January 25, 2021
Business News

Lassogen Raises Seed Round to Develop Novel Therapeutics for Challenging Targets

SAN DIEGO–()–Lassogen, a company dedicated to developing lasso peptides as an entirely new therapeutic modality, today announced that it has raised $4.5 million in an oversubscribed seed round of funding led by Playground Global with participation from Better Ventures, First In Ventures, Tsingyuan Ventures, and additional investors. Combined with pre-seed funding in 2019, Lassogen has raised investment capital totaling $5.1 million to date. The seed investment proceeds will enable the company to achieve key results that demonstrate the utility and promise of lasso peptides for treating serious human diseases such as cancer, autoimmunity, pain, and inflammation.

Lassogen is developing a new class of peptide…

Click here to view the original article.

Related Posts

You might also like ...

Cadence Bancorporation Reports Fourth Quarter and Full Year 2020 Financial Results
Vizient Invests with PPE Manufacturers to Expand U.S.-based Manufacturing and Help Stabilize Supply
BRS Media’s dotFM Releases Ranking of Top .FM Sites and Brands, .FM Top 100 Hits of 2020